Vir Biotechnology, Inc. (VIR) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Vir Biotechnology, Inc. (VIR) closed at USD 10.41 on 2026-10-14, a change of +61.9 % over the past year, with a market capitalization of USD 1.77B.

Vir Biotechnology, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Vir Biotechnology, Inc. key figures

Previous close

USD 10.41 (2026-10-14)

1-year change

+61.9 %

Market cap

USD 1.77B

Enterprise value

USD 1.33B

P/E ratio (trailing)

-6.02

P/E ratio (forward)

-4.21

EPS (trailing)

-1.74

EPS (forward)

-2.49

PEG ratio

n/a

Price to book

1.80

Revenue growth

19,582.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.87

Employees

367

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors. It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Vir Biotechnology, Inc. and compare it with other stocks.